<DOC>
	<DOCNO>NCT00858013</DOCNO>
	<brief_summary>This multi-center , randomize control study aim evaluate durability efficacy nateglinide therapy long term glycemic control compare glimepiride .</brief_summary>
	<brief_title>Study Durability Glycemic Control With Nateglinide</brief_title>
	<detailed_description>Selected patient randomly assign receive nateglinide glimepiride . Previous treatment oral antidiabetic drug ( metformin , a-glucosidase inhibitor , nateglinide sulfonylurea ) discontinue . After 1 month wash-out period ( 6.5 ≤ HbA1c ≤ 8.5 ) , patient take randomly assign drug 24 month . Patients meet trial investigator every 3 month follow randomization . At visit , patient whose HbA1c &gt; 8.0 % retested 2 week later , retested HbA1c also 8.0 % , patient withdraw consider monotherapy failure . We evaluate durability nateglinide comparison glimepiride base withdrawal rate .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Nateglinide</mesh_term>
	<criteria>type 2 diabetes mellitus age &gt; =18years anti hyperglycemic agent 3 month lowdose oral hypoglycemic therapy metformin≤1g/day , acarbose≤300mg/day , voglibose≤0.9mg/day , nateglinide≤270mg/day , gliclazide≤80mg/day , glimepiride≤2mg/day , glibenclamide≤5mg/day ( nateglinide sulfonylurea &lt; 6months ) 6.5 % ≤ HbA1c ≤ 8.5 % patient anti hyperglycemic agent 3 month : HbA1c screen patient oral hypoglycemic therapy 3months : HbA1c washout attend clinical trial 3months type I diabetes mellitus take systemic steroid 1month require steroid therapy clinical trial acute myocardial infarction 6months alcoholic , pituitary adrenal insufficiency , severe ketosis , diabetic ketoacidosis severe liver disease AST , ALT ≥ 2.5 x ULN renal insufficiency ( serum creatinine &gt; 2.0mg/dl ) severe diabetic complication drug hypersensitivity history nateglinide sulfonylurea pregnant plan become pregnant clinical trial , lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Nateglinide</keyword>
	<keyword>Pancreatic beta cell function</keyword>
</DOC>